Moderna announced Wednesday that the first participant has been dosed in the company s Phase 2 clinical trial of a coronavirus vaccine booster shot that is specific to the Omicron variant.
Moderna begins next phase of Omicron-specific booster trial as study finds that antibodies remain durable despite 6-fold drop over 6 months kvia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kvia.com Daily Mail and Mail on Sunday newspapers.
Moderna announced Wednesday that the first participant has been dosed in the company s Phase 2 clinical trial of a coronavirus vaccine booster shot that is specific to the Omicron variant.
Omicron currently accounts for 99.9% of U.S. COVID-19 infections, the U.S. Centers for Disease Control and Prevention said. The delta variant makes up the remaining 0.1%.